PURPOSE: Small cell undifferentiated (SCU) histology in hepatoblastoma (HB) tumors has historically been associated with a poor prognosis. Tumors from patients enrolled on Children's Oncology Group (COG) study AHEP0731 underwent institutional and central pathologic review for identification of SCU histology. PATIENTS AND METHODS: Patients with SCU histology identified at the local treating institution who had otherwise low-risk tumors were upstaged to the intermediate-risk treatment stratum, whereas those only identified by retrospective central review were treated per the local institution as low-risk. Patients with otherwise intermediate- or high-risk tumors remained in that treatment stratum, respectively. Central review was to be performed for all tissue samples obtained at any time point. Treatment was per local review, whereas analysis of outcome was based on central review. RESULTS: Thirty-five patients had some elements (1%-25%) of SCU identified on central review of diagnostic specimens. All but two patient tissue sample retained nuclear INI1 expression. The presence of SCU histology did not correlate with age, alpha-fetoprotein level at diagnosis, or sex. The presence of SCU did not affect event-free survival (EFS). EFS at 5 years for patients with low-risk, intermediate-risk, and high-risk with SCU HB was 86% (95% CI, 33 to 98), 81% (95% CI, 57 to 92), and 29% (95% CI, 4 to 61), respectively, compared with EFS at 5 years for patients without SCU enrolled with low-risk, intermediate-risk, and high-risk of 87% (95% CI, 72 to 95), 88% (95% CI, 79 to 94), and 55% (95% CI, 32 to 74; P = .17), respectively. CONCLUSION: The presence of SCU histology in HB does not appear to adversely affect outcome. Future studies should be able to treat patients with SCU HB according to risk stratification without regard to the presence of SCU histology.
PURPOSE: Small cell undifferentiated (SCU) histology in hepatoblastoma (HB) tumors has historically been associated with a poor prognosis. Tumors from patients enrolled on Children's Oncology Group (COG) study AHEP0731 underwent institutional and central pathologic review for identification of SCU histology. PATIENTS AND METHODS: Patients with SCU histology identified at the local treating institution who had otherwise low-risk tumors were upstaged to the intermediate-risk treatment stratum, whereas those only identified by retrospective central review were treated per the local institution as low-risk. Patients with otherwise intermediate- or high-risk tumors remained in that treatment stratum, respectively. Central review was to be performed for all tissue samples obtained at any time point. Treatment was per local review, whereas analysis of outcome was based on central review. RESULTS: Thirty-five patients had some elements (1%-25%) of SCU identified on central review of diagnostic specimens. All but two patient tissue sample retained nuclear INI1 expression. The presence of SCU histology did not correlate with age, alpha-fetoprotein level at diagnosis, or sex. The presence of SCU did not affect event-free survival (EFS). EFS at 5 years for patients with low-risk, intermediate-risk, and high-risk with SCU HB was 86% (95% CI, 33 to 98), 81% (95% CI, 57 to 92), and 29% (95% CI, 4 to 61), respectively, compared with EFS at 5 years for patients without SCU enrolled with low-risk, intermediate-risk, and high-risk of 87% (95% CI, 72 to 95), 88% (95% CI, 79 to 94), and 55% (95% CI, 32 to 74; P = .17), respectively. CONCLUSION: The presence of SCU histology in HB does not appear to adversely affect outcome. Future studies should be able to treat patients with SCU HB according to risk stratification without regard to the presence of SCU histology.
Authors: Howard M Katzenstein; Cynthia Rigsby; Peter H Shaw; Torrey L Mitchell; Paul R Haut; Morris Kletzel Journal: J Pediatr Hematol Oncol Date: 2002-12 Impact factor: 1.289
Authors: Christian Vokuhl; Florian Oyen; Beate Häberle; Dietrich von Schweinitz; Reinhard Schneppenheim; Ivo Leuschner Journal: Genes Chromosomes Cancer Date: 2016-07-29 Impact factor: 5.006
Authors: Rudolf Maibach; Derek Roebuck; Laurence Brugieres; Michael Capra; Penelope Brock; Patrizia Dall'Igna; Jean-Bernard Otte; Beatriz De Camargo; Jozsef Zsiros; Arthur Zimmermann; Daniel Aronson; Margaret Childs; Marcelo Scopinaro; Bruce Morland; Jack Plaschkes; Piotr Czauderna; Giorgio Perilongo Journal: Eur J Cancer Date: 2012-01-13 Impact factor: 9.162
Authors: József Zsíros; Rudolf Maibach; Elizabeth Shafford; Laurence Brugieres; Penelope Brock; Piotr Czauderna; Derek Roebuck; Margaret Childs; Arthur Zimmermann; Veronique Laithier; Jean-Bernard Otte; Beatriz de Camargo; Gordon MacKinlay; Marcelo Scopinaro; Daniel Aronson; Jack Plaschkes; Giorgio Perilongo Journal: J Clin Oncol Date: 2010-04-20 Impact factor: 44.544
Authors: Angela D Trobaugh-Lotrario; Gail E Tomlinson; Milton J Finegold; Lia Gore; James H Feusner Journal: Pediatr Blood Cancer Date: 2009-03 Impact factor: 3.167
Authors: Maretta De Ioris; Laurence Brugieres; Arthur Zimmermann; Jean Keeling; Penelope Brock; Rudolf Maibach; Jon Pritchard; Liz Shafford; Joszef Zsiros; Piotr Czaudzerna; Giorgio Perilongo Journal: Eur J Cancer Date: 2007-12-31 Impact factor: 9.162
Authors: I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre Journal: Nature Date: 1998-07-09 Impact factor: 49.962